News
EDSA
5.43
+2.45%
0.13
Edesa Biotech Q3 EPS $(0.60) Misses $(0.58) Estimate
Benzinga · 2h ago
Edesa Biotech GAAP EPS of -$0.60 misses by $0.17
Seeking Alpha · 2h ago
Press Release: Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results
Dow Jones · 3h ago
Press Release: Edesa Biotech Reports Fiscal 3rd -2-
Dow Jones · 3h ago
Weekly Report: what happened at EDSA last week (0803-0807)?
Weekly Report · 3d ago
Weekly Report: what happened at EDSA last week (0727-0731)?
Weekly Report · 08/03 09:09
Weekly Report: what happened at EDSA last week (0720-0724)?
Weekly Report · 07/27 09:10
Weekly Report: what happened at EDSA last week (0713-0717)?
Weekly Report · 07/20 09:09
Weekly Report: what happened at EDSA last week (0706-0710)?
Weekly Report · 07/13 09:09
Weekly Report: what happened at EDSA last week (0629-0703)?
Weekly Report · 07/06 09:10
Edesa Biotech files to sell 729,241 common shares for holders
TipRanks · 07/02 21:05
Edesa Biotech reinstated with a Buy at Brookline
TipRanks · 06/29 19:50
Weekly Report: what happened at EDSA last week (0622-0626)?
Weekly Report · 06/29 09:09
Top Biotech Gainers: BOLD Begins Anew, MNPR NDA Filing On Track, GALT Soars On FDA Alignment
NASDAQ · 06/24 03:13
Weekly Report: what happened at EDSA last week (0615-0619)?
Weekly Report · 06/22 09:11
Weekly Report: what happened at EDSA last week (0608-0612)?
Weekly Report · 06/15 09:10
Edesa Enters PIPE Placement Worth $3.5 Mln With Investors And CEO
NASDAQ · 06/12 10:57
Edesa Biotech Announces Insider-Led PIPE Financing Agreement
TipRanks · 06/11 13:49
Edesa Biotech announces $3.5M PIPE financing
Seeking Alpha · 06/11 13:45
Edesa Biotech announces $3.5M private placement
TipRanks · 06/11 13:27
More
Webull provides a variety of real-time EDSA stock news. You can receive the latest news about Edesa Biotech Inc through multiple platforms. This information may help you make smarter investment decisions.
About EDSA
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.